A Phase II Study of Telisotuzumab Vedotin in Patients With c-MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753)
Telisotuzumab Vedotin 在 c-MET 阳性 IV 期或复发性鳞状细胞肺癌患者中的 II 期研究（LUNG-MAP 子研究 S1400K，NCT03574753）
期刊:Clinical Lung Cancer
影响因子:3.3
doi:10.1016/j.cllc.2020.09.013
Waqar, Saiama N; Redman, Mary W; Arnold, Susanne M; Hirsch, Fred R; Mack, Philip C; Schwartz, Lawrence H; Gandara, David R; Stinchcombe, Thomas E; Leighl, Natasha B; Ramalingam, Suresh S; Tanna, Saloni H; Raddin, Ryan S; Minichiello, Katherine; Bradley, Jeffrey D; Kelly, Karen; Herbst, Roy S; Papadimitrakopoulou, Vassiliki A
